Literature DB >> 28910489

Nucleoside/nucleotide reverse transcriptase inhibitors attenuate angiogenesis and lymphangiogenesis by impairing receptor tyrosine kinases signalling in endothelial cells.

Lin Song1,2,3, Sha Ding1,2,3, Zhen Ge4, Xiaolong Zhu1,2,3, Cong Qiu1,2,3, Yuewen Wang1,2,3, Enyin Lai5, Weijun Yang1, Yi Sun1, Samson A Chow6, Luyang Yu1,2,3.   

Abstract

BACKGROUND AND
PURPOSE: Cardiovascular disease associated with antiretroviral therapy (ART) has become a major clinical challenge for HIV-positive patients. However, the role of ART in blood vessel growth is largely unknown. Here, we examined an integral component of ART, nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and investigated their effects on key microvascular functions, including angiogenesis and lymphangiogenesis. EXPERIMENTAL APPROACH: The angiogenesis/lymphangiogenesis capability of endothelial cells (ECs) was evaluated using migration, proliferation and tube formation assays in vitro, and mouse ear and Matrigel plug assays in vivo. Expressions of signalling molecules and mitochondrial antioxidant catalases were determined using Western blotting. Receptor tyrosine kinase (RTK) internalization and endocytosis were examined using flow cytometry and confocal immunofluorescence microscopy respectively. Mitochondrial DNA copy number and ROS were determined using quantitative real-time PCR and MitoSOX staining respectively. KEY
RESULTS: Pharmaceutical doses of NRTIs [azidothymidine (AZT), tenofovir disoproxil fumarate (TDF) and lamivudine (3TC)] inhibited angiogenesis and lymphangiogenesis both in vivo and in vitro by affecting the proliferation and migration of ECs. Correspondingly, NRTIs selectively attenuated the activation and transduction of endothelial RTK signals, VEGFR2 and FGFR1 pathways, in vascular ECs and the VEGFR3 pathway in lymphatic ECs. Both TDF and 3TC restrained RTKs' endocytosis into early endosomes but not internalization, while AZT blocked the protein maturation of RTKs. Excessive ROS levels were detected in NRTI-treated ECs, and the MnSOD mimic MnTMPyP alleviated the angiogenic/lymphangiogenic defects induced by NRTIs. CONCLUSIONS AND IMPLICATIONS: NRTIs negatively regulate angiogenesis and lymphangiogenesis by inducing mitochondrial oxidative stress and subsequently impairing RTK signalling in ECs. LINKED ARTICLES: This article is part of a themed section on Spotlight on Small Molecules in Cardiovascular Diseases. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.8/issuetoc.
© 2017 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28910489      PMCID: PMC5866989          DOI: 10.1111/bph.14036

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  80 in total

1.  VEGF-C signaling pathways through VEGFR-2 and VEGFR-3 in vasculoangiogenesis and hematopoiesis.

Authors:  K Hamada; Y Oike; N Takakura; Y Ito; L Jussila; D J Dumont; K Alitalo; T Suda
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

Review 2.  HIV infection and cardiovascular disease.

Authors:  Lars G Hemkens; Heiner C Bucher
Journal:  Eur Heart J       Date:  2014-01-09       Impact factor: 29.983

3.  Experimental design and analysis and their reporting: new guidance for publication in BJP.

Authors:  Michael J Curtis; Richard A Bond; Domenico Spina; Amrita Ahluwalia; Stephen P A Alexander; Mark A Giembycz; Annette Gilchrist; Daniel Hoyer; Paul A Insel; Angelo A Izzo; Andrew J Lawrence; David J MacEwan; Lawrence D F Moon; Sue Wonnacott; Arthur H Weston; John C McGrath
Journal:  Br J Pharmacol       Date:  2015-07       Impact factor: 8.739

4.  The Concise Guide to PHARMACOLOGY 2015/16: Enzymes.

Authors:  Stephen Ph Alexander; Doriano Fabbro; Eamonn Kelly; Neil Marrion; John A Peters; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies
Journal:  Br J Pharmacol       Date:  2015-12       Impact factor: 8.739

5.  The Critical Role of Dynamin-Related Protein 1 in Hypoxia-Induced Pulmonary Vascular Angiogenesis.

Authors:  Tingting Shen; Na Wang; Xiufeng Yu; Jiucheng Shi; Qian Li; Chen Zhang; Li Fu; Shuang Wang; Yan Xing; Xiaodong Zheng; Lei Yu; Daling Zhu
Journal:  J Cell Biochem       Date:  2015-09       Impact factor: 4.429

6.  Aspects of fatty acid metabolism in vascular endothelial cells.

Authors:  W C Hülsmann; M L Dubelaar
Journal:  Biochimie       Date:  1988-05       Impact factor: 4.079

Review 7.  Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy.

Authors:  Masuko Ushio-Fukai; Yoshimasa Nakamura
Journal:  Cancer Lett       Date:  2008-04-10       Impact factor: 8.679

8.  VEGFR3 does not sustain retinal angiogenesis without VEGFR2.

Authors:  Georgia Zarkada; Krista Heinolainen; Taija Makinen; Yoshiaki Kubota; Kari Alitalo
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-05       Impact factor: 11.205

Review 9.  Current Scenario of HIV/AIDS, Treatment Options, and Major Challenges with Compliance to Antiretroviral Therapy.

Authors:  Adnan Bashir Bhatti; Muhammad Usman; Venkataramana Kandi
Journal:  Cureus       Date:  2016-03-01

10.  Non-Classical Monocytes and Monocyte Chemoattractant Protein-1 (MCP-1) Correlate with Coronary Artery Calcium Progression in Chronically HIV-1 Infected Adults on Stable Antiretroviral Therapy.

Authors:  Nath Zungsontiporn; Raquel R Tello; Guangxiang Zhang; Brooks I Mitchell; Matthew Budoff; Kalpana J Kallianpur; Beau K Nakamoto; Sheila M Keating; Philip J Norris; Lishomwa C Ndhlovu; Scott A Souza; Cecilia M Shikuma; Dominic C Chow
Journal:  PLoS One       Date:  2016-02-11       Impact factor: 3.240

View more
  9 in total

1.  Nucleoside/nucleotide reverse transcriptase inhibitors attenuate angiogenesis and lymphangiogenesis by impairing receptor tyrosine kinases signalling in endothelial cells.

Authors:  Lin Song; Sha Ding; Zhen Ge; Xiaolong Zhu; Cong Qiu; Yuewen Wang; Enyin Lai; Weijun Yang; Yi Sun; Samson A Chow; Luyang Yu
Journal:  Br J Pharmacol       Date:  2017-10-25       Impact factor: 8.739

2.  Spotlight on small molecules in cardiovascular diseases.

Authors:  Xin Wang; Yu Huang; Yong Ji
Journal:  Br J Pharmacol       Date:  2018-04       Impact factor: 8.739

3.  Icariin protects cardiomyocytes against ischaemia/reperfusion injury by attenuating sirtuin 1-dependent mitochondrial oxidative damage.

Authors:  Bing Wu; Jian-Yu Feng; Li-Ming Yu; Yan-Chun Wang; Yong-Qing Chen; Yan Wei; Jin-Song Han; Xiao Feng; Yu Zhang; Shou-Yin Di; Zhi-Qiang Ma; Chong-Xi Fan; Xiao-Qin Ha
Journal:  Br J Pharmacol       Date:  2018-09-21       Impact factor: 8.739

Review 4.  The Impact of Matrix Metalloproteinase-9 on the Sequential Steps of the Metastatic Process.

Authors:  Giovanni Barillari
Journal:  Int J Mol Sci       Date:  2020-06-25       Impact factor: 5.923

Review 5.  The Anti-Angiogenic Effects of Anti-Human Immunodeficiency Virus Drugs.

Authors:  Giovanni Barillari
Journal:  Front Oncol       Date:  2020-05-21       Impact factor: 6.244

Review 6.  Maternal endothelial dysfunction in HIV-associated preeclampsia comorbid with COVID-19: a review.

Authors:  Nitalia Naidoo; Jagidesa Moodley; Thajasvarie Naicker
Journal:  Hypertens Res       Date:  2021-01-20       Impact factor: 5.528

Review 7.  Approved HIV reverse transcriptase inhibitors in the past decade.

Authors:  Guangdi Li; Yali Wang; Erik De Clercq
Journal:  Acta Pharm Sin B       Date:  2021-11-16       Impact factor: 14.903

Review 8.  Neuropilin-1 in the pathogenesis of preeclampsia, HIV-1, and SARS-CoV-2 infection: A review.

Authors:  Nitalia Naidoo; Jagidesa Moodley; Olive Pearl Khaliq; Thajasvarie Naicker
Journal:  Virus Res       Date:  2022-07-26       Impact factor: 6.286

9.  Role of R-spondin 2 in arterial lymphangiogenesis and atherosclerosis.

Authors:  Bhupesh Singla; Hui-Ping Lin; Alex Chen; WonMo Ahn; Pushpankur Ghoshal; Mary Cherian-Shaw; Joseph White; Brian K Stansfield; Gábor Csányi
Journal:  Cardiovasc Res       Date:  2021-05-25       Impact factor: 10.787

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.